Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tsukasa Matsubara

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 22, 2013
[Abatacept]Takeshi Nakamura, Tsukasa Matsubara
Clinical Rheumatology|August 3, 2012
What RA patients expect of their treatment--discussion over the result of our surveyKeiko Funahashi, Tsukasa Matsubara
Modern Rheumatology|October 6, 2018
A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexateHiroaki Matsuno, Tsukasa Matsubara
Modern Rheumatology|July 15, 2016
Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritisKeiko Funahashi, Satoru Koyano, Hirotoshi Echizen, et al.
Clinical and Experimental Rheumatology|July 10, 2019
Choice of the most appropriate biological disease-modifying anti-rheumatic drug for injection spacing: results from a multicentre observational studyHiroaki Matsuno, Kou Katayama, Keiko Funahashi, et al.
Modern Rheumatology|December 13, 2021
Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 studyYoshiya Tanaka, Tsukasa Matsubara, Koichi Hashizume, et al.
Modern Rheumatology|January 25, 2012
Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activityMasayoshi Harigai, Tsutomu Takeuchi, Yoshiya Tanaka, et al.
Modern Rheumatology|September 20, 2017
Erratum to: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activityMasayoshi Harigai, Tsutomu Takeuchi, Yoshiya Tanaka, et al.
Modern Rheumatology|July 18, 2009
Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 levelKeiko Funahashi, Satoru Koyano, Takako Miura, et al.
The Journal of Dermatology|May 1, 2016
Genetic prediction of the effectiveness of biologics for psoriasis treatmentRika Nishikawa, Hiroshi Nagai, Toshinori Bito, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 22, 2013
[Abatacept]Takeshi Nakamura, Tsukasa Matsubara
Clinical Rheumatology|August 3, 2012
What RA patients expect of their treatment--discussion over the result of our surveyKeiko Funahashi, Tsukasa Matsubara
Modern Rheumatology|October 6, 2018
A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexateHiroaki Matsuno, Tsukasa Matsubara
Modern Rheumatology|July 15, 2016
Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritisKeiko Funahashi, Satoru Koyano, Hirotoshi Echizen, et al.
Clinical and Experimental Rheumatology|July 10, 2019
Choice of the most appropriate biological disease-modifying anti-rheumatic drug for injection spacing: results from a multicentre observational studyHiroaki Matsuno, Kou Katayama, Keiko Funahashi, et al.
Modern Rheumatology|December 13, 2021
Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 studyYoshiya Tanaka, Tsukasa Matsubara, Koichi Hashizume, et al.
Modern Rheumatology|January 25, 2012
Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activityMasayoshi Harigai, Tsutomu Takeuchi, Yoshiya Tanaka, et al.
Modern Rheumatology|September 20, 2017
Erratum to: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activityMasayoshi Harigai, Tsutomu Takeuchi, Yoshiya Tanaka, et al.
Modern Rheumatology|July 18, 2009
Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 levelKeiko Funahashi, Satoru Koyano, Takako Miura, et al.
The Journal of Dermatology|May 1, 2016
Genetic prediction of the effectiveness of biologics for psoriasis treatmentRika Nishikawa, Hiroshi Nagai, Toshinori Bito, et al.
Pageof 7